SG11202100208VA - Fusion constructs and methods of using thereof - Google Patents

Fusion constructs and methods of using thereof

Info

Publication number
SG11202100208VA
SG11202100208VA SG11202100208VA SG11202100208VA SG11202100208VA SG 11202100208V A SG11202100208V A SG 11202100208VA SG 11202100208V A SG11202100208V A SG 11202100208VA SG 11202100208V A SG11202100208V A SG 11202100208VA SG 11202100208V A SG11202100208V A SG 11202100208VA
Authority
SG
Singapore
Prior art keywords
methods
fusion constructs
constructs
fusion
Prior art date
Application number
SG11202100208VA
Other languages
English (en)
Inventor
Helen Sabzevari
Simon Metenou
Changhung Chen
Rutul R Shah
Original Assignee
Precigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precigen Inc filed Critical Precigen Inc
Publication of SG11202100208VA publication Critical patent/SG11202100208VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202100208VA 2018-07-09 2019-07-09 Fusion constructs and methods of using thereof SG11202100208VA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862695627P 2018-07-09 2018-07-09
US201862695623P 2018-07-09 2018-07-09
US201962863710P 2019-06-19 2019-06-19
US201962864367P 2019-06-20 2019-06-20
US201962866420P 2019-06-25 2019-06-25
PCT/US2019/041085 WO2020014285A2 (en) 2018-07-09 2019-07-09 Fusion constructs and methods of using thereof

Publications (1)

Publication Number Publication Date
SG11202100208VA true SG11202100208VA (en) 2021-02-25

Family

ID=69141640

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100208VA SG11202100208VA (en) 2018-07-09 2019-07-09 Fusion constructs and methods of using thereof

Country Status (11)

Country Link
US (2) US11535669B2 (https=)
EP (1) EP3820496A4 (https=)
JP (2) JP7617839B2 (https=)
KR (1) KR20210042909A (https=)
CN (2) CN112672753B (https=)
AU (1) AU2019301070B2 (https=)
CA (1) CA3105750A1 (https=)
IL (1) IL279965A (https=)
SG (1) SG11202100208VA (https=)
WO (1) WO2020014285A2 (https=)
ZA (2) ZA202100390B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US11771718B2 (en) * 2017-10-18 2023-10-03 Precigen, Inc. Polypeptide compositions comprising spacers
WO2020127369A1 (en) * 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
CN110734498A (zh) * 2019-10-15 2020-01-31 上海科棋药业科技有限公司 一种用于解除免疫抑制的融合蛋白及其应用
CN114616251B (zh) * 2019-10-21 2024-05-24 南京维立志博生物科技有限公司 靶向PD-1和TGFβ的重组蛋白
WO2021084124A1 (en) 2019-11-01 2021-05-06 Ares Trading S.A. COMBINED INHIBITION OF PD-1, TGFβ AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
IL292758A (en) 2019-11-05 2022-07-01 Merck Patent Gmbh Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
EP4097220A4 (en) * 2020-01-30 2024-03-20 ImmunityBio, Inc. ELIMINATION OF BCMA-POSITIVE MALIGNANCIES BY CAR-EXPRESSING NK CELLS
WO2021185337A1 (zh) * 2020-03-20 2021-09-23 荣昌生物制药(烟台)股份有限公司 一种双特异性融合蛋白及其应用
CA3175490A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Limited Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
BR112022022020A2 (pt) * 2020-04-29 2023-01-31 Chia Tai Tianqing Pharmaceutical Group Co Ltd Proteína bifuncional contra pd-1 e tgf-ss
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
CN113754771A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pdl1×egfr的双特异性抗体
JP2023532279A (ja) * 2020-06-26 2023-07-27 ソレント・セラピューティクス・インコーポレイテッド 免疫調節性融合タンパク質を発現する腫瘍溶解性単純ヘルペスウイルス（ｈｓｖ）
WO2022011256A1 (en) * 2020-07-10 2022-01-13 Precigen, Inc. Fusion constructs and methods of using thereof
CN116323658A (zh) * 2020-09-28 2023-06-23 上海君实生物医药科技股份有限公司 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途
US20230372319A1 (en) 2020-11-02 2023-11-23 Ares Trading S.A. Combination Treatment of Cancer
AU2021372815A1 (en) 2020-11-02 2023-06-22 Ares Trading S.A. Combination treatment of cancer
AU2021389989A1 (en) * 2020-11-27 2023-06-08 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfβeta
KR20230146032A (ko) * 2021-02-15 2023-10-18 다케다 야쿠힌 고교 가부시키가이샤 Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법
WO2022174451A1 (zh) * 2021-02-22 2022-08-25 浙江道尔生物科技有限公司 一种具有抗癌活性的多结构域融合蛋白
CN112979802B (zh) * 2021-04-21 2021-08-03 上海普铭生物科技有限公司 抗人il-33单克隆抗体及其应用
CN113249330A (zh) * 2021-05-20 2021-08-13 深圳市先康达生命科学有限公司 免疫细胞及其应用
EP4351640A1 (en) 2021-06-07 2024-04-17 Ares Trading S.A. Combination treatment of cancer
JP2024532382A (ja) * 2021-08-30 2024-09-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー アデノシンデアミナーゼの細胞表面発現を有するｔ細胞及びその使用
KR20240050428A (ko) * 2021-08-31 2024-04-18 더 텍사스 에이 앤드 엠 유니버시티 시스템 키메라 항원 수용체(car) t 세포 요법 플랫폼
EP4396240A4 (en) * 2021-09-03 2025-06-11 Pulmongene (Hong Kong) Co., Limited BIFUNCTIONAL FUSION PROTEIN AND USES THEREOF
WO2023086920A2 (en) * 2021-11-12 2023-05-19 Georgia Tech Research Corporation Adenosine deaminase 2 compositions and methods for using same
WO2023125289A1 (zh) * 2021-12-31 2023-07-06 上海宏成药业有限公司 抗pd-1抗体及其用途
CN114540311A (zh) * 2022-02-24 2022-05-27 深圳市先康达生命科学有限公司 一种免疫细胞及其应用
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP0973888A1 (en) 1997-02-06 2000-01-26 Human Genome Sciences, Inc. Dendritic cell-derived growth factor
NZ500284A (en) 1997-04-18 2001-09-28 Biogen Inc Type II TGF-beta receptor fusion proteins
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
WO2010020767A2 (en) * 2008-08-21 2010-02-25 Asterion Limited Glp-1 fusion polypeptides
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US20150086584A1 (en) 2012-03-22 2015-03-26 University Of Miami Multi-specific binding agents
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
WO2013169693A1 (en) * 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
AU2014309199B2 (en) * 2013-08-20 2018-04-19 Merck Sharp & Dohme Llc Treating cancer with a combination of a PD-1 antagonist and dinaciclib
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
BR112016014952A2 (pt) 2014-02-10 2017-09-19 Merck Patent Gmbh Inibição direcionada de tgfbeta
CA2945388A1 (en) * 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
US20190048085A1 (en) 2016-02-25 2019-02-14 Cell Medica Switzerland Ag Modified cells for immunotherapy
WO2018017144A1 (en) * 2016-07-19 2018-01-25 Brandeis University Compositions and methods for identifying rna binding polypeptide targets
AU2017310027A1 (en) 2016-08-12 2019-01-31 Merck Patent Gmbh Combination therapy for cancer
BR112019005964A2 (pt) 2016-09-27 2019-06-18 Epicentrx, Inc. proteínas de fusão imunomoduladoras
WO2018129331A1 (en) 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
ES2948647T3 (es) 2017-05-04 2023-09-15 Acceleron Pharma Inc Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas
AU2018266103B2 (en) 2017-05-09 2024-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
MY202480A (en) 2017-05-12 2024-04-30 Shanghai hengrui pharmaceutical co ltd Fusion protein containing tgf- receptor and medicinal uses thereof
MX2020011684A (es) * 2018-05-04 2020-12-10 Merck Patent Gmbh Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
CN113226335B (zh) * 2018-12-06 2023-10-13 广东天科雅生物医药科技有限公司 靶向肿瘤抗原、TGF-β、和免疫检查点的组合型TCR-T细胞疗法
CN109913425B (zh) * 2019-03-22 2021-05-11 中国人民解放军总医院第五医学中心 一种重组流感病毒拯救方法及其在肿瘤治疗中的应用
WO2020263796A1 (en) 2019-06-23 2020-12-30 Guangdong Tcrcure Biopharma Technology Co., Ltd. Anti-alpp car-t cell therapy

Also Published As

Publication number Publication date
WO2020014285A3 (en) 2020-03-12
IL279965A (en) 2021-03-01
CN112672753B (zh) 2025-07-08
EP3820496A4 (en) 2022-04-20
JP2025063123A (ja) 2025-04-15
US20200048351A1 (en) 2020-02-13
AU2019301070B2 (en) 2025-09-11
JP7617839B2 (ja) 2025-01-20
AU2019301070A1 (en) 2021-01-21
WO2020014285A2 (en) 2020-01-16
ZA202100390B (en) 2023-10-25
CN112672753A (zh) 2021-04-16
CN120775065A (zh) 2025-10-14
US11535669B2 (en) 2022-12-27
JP2021531754A (ja) 2021-11-25
EP3820496A2 (en) 2021-05-19
KR20210042909A (ko) 2021-04-20
ZA202300423B (en) 2025-04-30
CA3105750A1 (en) 2020-01-16
US20240141045A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
SG11202100208VA (en) Fusion constructs and methods of using thereof
IL288373A (en) flt3l-fc fusion proteins and methods of use
IL280102A (en) Fusion protein containing PD1-4-1BBL and methods of using it
SI4186920T1 (sl) Ultra dolgo delujoči inzulin-FC fuzijski proteini in postopki uporabe
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
IL265605A (en) Structures of immunoglobulin heterodimers and methods for their preparation
IL275070A (en) FCRN antibodies and methods of using them
PT3618863T (pt) Anticorpos anti-tigit e seus métodos de utilização
IL267861A (en) PD1-41BBL conjugate protein and methods of using it
CA3253735A1 (en) Chimeric antigen receptors and methods of use
IL267862A (en) SIRPalpha-41BBL conjugate protein and methods of using it
IL280103A (en) Fusion protein containing SIRPalpha-4-1BBL and methods of using it
EP3261650A4 (en) Anti-dll3 chimeric antigen receptors and methods of use
SG11202102644XA (en) Methods and uses of variant cd80 fusion proteins and related constructs
EP3706786A4 (en) BIS SPECIFIC FUSION POLYPEPTIDES AND METHOD OF USING THEREOF
IL274221A (en) Antibodies to ANTI-APOC3 and methods of use
IL277212A (en) Anti-KLK5 antibodies and methods of use
IL276187A (en) MICA/B antibodies and methods of use
ZA202002144B (en) Antibodies and methods of use
IL268234A (en) Factor ix fusion proteins and methods of making and using same
IL286799A (en) Consolidated structures and their uses
HK40042278A (zh) 融合构建体及其使用方法
HK40037115A (en) Modified chimeric antigen receptors and methods of use
HK40037614A (en) Bispecific fusion polypeptides and methods of use thereof
HK40038054A (en) Fcrn antibodies and methods of use thereof